Navigation Links
AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Date:10/19/2009

solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This offering is being made by means of a prospectus supplement to the Company's existing base prospectus that is part of its shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements con
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
2. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
3. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
4. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
5. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
7. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
8. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
9. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
10. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
11. AEterna Zentaris Receives US$10 Million from Institutional Investors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...wire-FirstCall/ -- BioMarin Pharmaceutical Inc. (N...rug Administration (FDA) has granted orphan drug d...ampridine phosphate, for the rare autoimmune disea...DAP has previously received orphan drug designatio...e for Medicinal Products for Human Use of the Euro...
(Date:11/30/2009)...Newswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), a...l-device research and,development outsourcing comp...,announced that it had been selected to the Deloi...th consecutive year. The list recognizes the 50,fa...ia, and telecommunications,industries based on rev...
(Date:11/28/2009)...onal Advisory Committee on Climate Change (NACCC) ...oject in collaboration with the Vanuatu Meteorolog...have generated preliminary climate change and sea ...or the country’s SNC reporting to the United...NFCCC). , Port Vila, Van...
(Date:11/26/2009)...ion of ultrasmall transistors and more powerful co...ucting nanowires are closer to reality after a key...y and the University of California at Los Angeles....nowires with layers of different materials that ar...critical requirement for making efficient transist...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
...a more proactive approach to collection and..., India and WESTBOROUGH, Mass., June 26 /PRNewswir...E: SAY ), a leading global consulting,and informa... that it has,formed an alliance with Sciformix Cor...Knowledge Process Outsourcing (KPO) company, to de...
...ngress by sepsis thought ...tCall/ - Spectral Diagnostics Inc.,(TSX: SDI) toda...ates the,combined clinical effectiveness of its En...red diagnostic for the measurement of endotoxin, t... and to guide endotoxin,reducing strategies, such ...
...ed a signature for water inside single-walled carb... structured and how it moves within these tiny cha...able to get a snapshot of the water inside the car...SWCNTs) offer the potential to act as a unique nan...rated extremely fast flow in these channels, it is...
Other Biology Technology:Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 2Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 3Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 4Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics 2LLNL researchers peer into water in carbon nanotubes 2
(Date:11/26/2009)...ococcus Aureus ) and other drug-resistant bacteria... prototype devices have been developed to offer sa...ls. , Two prototype devices have been developed:....g. hands and feet) in hospitals and public spaces...her to shoot bacteria-killing agents into infested...
(Date:11/25/2009)...l Death Research Laboratory in the University of H... prestigious Johnson & Johnson Focused Funding gra...ell damage in Parkinson,s disease. The award, whic... innovation and excellence in science, was announc...month at an event at the Hyatt Regency Hotel in Ne...
(Date:11/24/2009)...rescribed by traditional healers in Brazil to trea...ain to fever and flu. , Now for the first time, r...to scientifically prove the pain relieving propert...ian mint. , Testing this ancient South American h...ocha was able to show that when prepared as a ,tea...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering 6063 1Prevention experts urge modification to 2009 H1N1 guidance for health care workers 60874 1Prevention experts urge modification to 2009 H1N1 guidance for health care workers 60874 2Ants are friendly to some trees but not others 10648 1Ants are friendly to some trees but not others 10648 2
...urring more frequently than at any time in the las...lian-based scientists. , Investigations by Associa...xcellence in Coral Reef Studies and The University...uinea show how often the reefs were ‘wiped out?by ...nd was in stark contrast to what we see in the mod...
...rvation Society (WCS) and U.S. Geological Survey (...un national parks lose nearly a quarter of their p...ality, yet their numbers remain stable due to a co...prey. The study, which appears in the journal Eco...d areas with high prey densities in an overall tig...
...pears that nature prefers to build its proteins ar...ning advanced computational modeling and cutting-e...iversity and Baylor College of Medicine suggests t...e parts that fold first. , The findings appear i... Nature refuses to choose between form and functio...
Other Biology News:Coral stress 'like never in history' 2Wild tigers need cat food 2Protein folding: Building a strong foundation 2
...lized White solid. PACKAGED UNDER INERT GAS. DO ...ide resin with applications similar to those of DT...5 ) but with the important advantage that no solub...™ Reagent can be used in a batch technique, ...
Cleland’s Reagent, Molecular Biology Grade from Calbiochem
...pan, also named Sendai virus) Envelope VECTOR KIT ...f membrane fusion. Most efficient transfection are...s, Vector, and Biomolecule in vitro and in vivo. ...ort period of time that benetif sensitive primary ...
Cleland’s Reagent, ULTROL® Grade from Calbiochem
Biology Products: